U.S,Ca:18006380796

Contact Us

Get 30% Free Customization on This Report

Published Date: August, 2017

Exocrine Pancreatic Insufficiency Market: Global Industry Analysis, Trends, Market Size, and, Forecasts up to 2023


Request Discount Enquire Before Buying

Exocrine Pancreatic Insufficiency Market

Figure : Exocrine Pancreatic Insufficiency Market by Value 2015 - 2023


Exocrine pancreatic insufficiency (EPI) is a serious digestive problem and caused by improper digestion, and exocrine pancreatic insufficiency. It is a kind of a chronic disease caused by deficiency in pancreatic enzyme. Global revenue of exocrine pancreatic insufficiency market, was valued at more than USD 700 million in 2015, and is projected to surpass USD X.X Billion by 2023. Furthermore, the global exocrine pancreatic market is anticipated to grow at a CAGR between 8.0% – 8.6% over the period of 2017 to 2023. Increasing global incidences for exocrine pancreatic insufficiency is one of the prime reasons increasing demand of advanced therapeutics globally. Furthermore, presence of significant number of pipeline drugs and lipase treatment in diabetic patients, optimizes the chymotrypsin and trypsin level are expected to drive the global market for exocrine pancreatic insufficiency market over the forecast period. Moreover, the EPI market has been segmented by the mode of disease management, therapeutics drugs, diagnostic tests and geography. Mode of disease management contains nutrition management, PERT. Therapeutics drugs consist Creon, Zenpep, Pancreaze, Ultresa and Pertzye.

The report covers the analysis of exocrine pancreatic insufficiency market by therapeutics and diagnostic tests. Furthermore, the report covers the analysis of global as well as regional markets of exocrine pancreatic insufficiency. North America dominated the global market of exocrine pancreatic insufficiency by accounting for the largest market share. While the Asia Pacific region is expected to grow at a highest CAGR over the forecast period 2017 – 2023. Moreover, the report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand globally as well as regionally. Moreover, Infinium Global Research- Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.

The report provides insights into the market using analytical tools such as Porter’s five forces analysis exocrine pancreatic insufficiency market. Moreover, the study highlights current market trends and provides forecast from 2017 to 2023. We also have highlighted future trends in the exocrine pancreatic insufficiency market that will impact the demand during the forecast period. The Infinium Global Research- Growth Matrix analysis provided in this report highlights key investing markets in the world. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.


Companies Profiles:

The report on EPI market covers the companies such as Abbie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. MSD.

The report also provides in depth analysis of regulatory framework pertaining to Exocrine Pancreatic Insufficiency Market This will help the companies to understand the regulatory compliances, supports, barriers in the Exocrine Pancreatic Insufficiencymarket. This section highlights key amendments and their implication on Exocrine Pancreatic Insufficiency market in the short run as well as in the long run.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

Related Reports

sign up for our newsletter